Health-related quality of life outcomes among vedolizumab-treated patients with inflammatory bowel disease in the UK and Ireland: a 52-week observational study (OCTAVO).

J Patient Rep Outcomes · 2025 · PMC12214154 · PMID 40591206

Europe PMC DOI

hedged sentence

0.0550

closest p · 1.1× alpha

0.0550

boldest claim

The sentences

did not reach statistical significancep = 0.055so close (0.05 < p ≤ 0.1)

While there was a general trend suggesting that overall RFIPC scores improved post-index, the effect of time on the change in overall RFIPC score among patients in the CD cohort post-index did not reach statistical significance ( p = 0.055, n = 14).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.